What does the evidence say about Sulforaphane Oxidative Stress Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Sulforaphane Oxidative Stress Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - In whole blood, Kelch-like ECH-associating protein 1 (KEAP1) and catalase (CAT) mRNA levels were significantly reduced in iSLE and qSLE. [Liu L (2026); evidence level 4] - In conclusion, in qSLE patients, oxidative stress is elevated, while antioxidant capacity is decreased. [Liu L (2026); evidence level 4] - To elucidate whether it is already present in early phases, we investigate oxidative stress-related genes in incomplete SLE (iSLE) and quiescent SLE (qSLE, inactive disease), as well as the effect of nuclear factor erythroid-derived 2-like 2 (NRF2) activators on NRF2-related genes in peripheral blood mononuclear cells (PBMCs) and HaCaT keratinocytes. [Liu L (2026); evidence level 4] - In total, 28 qSLE patients, 29 iSLE patients and 21 age- and sex-matched healthy controls (HCs) were included. [Liu L (2026); evidence level 4] - Sulforaphane Mitigates Oxidative Stress in Alzheimer's Disease (AD) through NRF2 Activation [Khan Wasi Uzzaman (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.